Alan Tan, MD, discusses upcoming trials that could change the landscape of frontline and adjuvant renal cell carcinoma ...

On January 7, 2025, the FDA granted priority review to the new drug application for sunvozertinib (DZD9008), an oral EGFR ...

Merck & Co. (NYSE:MRK) is a prominent American multinational pharmaceutical company many investors know for its brand-name ...

Exelixis, Inc. EXEL reported better-than-expected fourth-quarter results. EXEL recorded earnings of 55 cents per share, which beat the Zacks Consensus Estimate of 51 cents. The company registered ...

"We will continue to work closely with the authorities toward approval in the EU." Welireg generated $139 million in sales during 2024’s third quarter and is the only approved HIF-2α inhibitor ...

The team are now recruiting patients into a new trial called LITESPARK-022 that combines Keytruda with MSD’s HIF-2 inhibitor Welireg (belzutifan) as an adjuvant treatment for RCC. Welireg was ...

Exelixis, Inc. (Nasdaq: EXEL) today reported financial results for the fourth quarter and fiscal year of 2024, provided an update on progress toward achieving key ...

Clinical trials are vital for advancing cancer treatment, yet only 5% to 7% of adult cancer patients participate due to various barriers. Misconceptions about clinical trials as a "last resort" or ...

In a clinical trial, patients treated with a kidney cancer vaccine remained cancer-free after a median of nearly three years.